Fassnacht M, Assie G, Baudin E, Eisenhofer G, de la Fouchardiere C, Haak HR, de Krijger R, Porpiglia F, Terzolo M, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(11):1476–1490. https://doi.org/10.1016/j.annonc.2020.08.2099

S-GRAS score for prognostic classification of, Elhassan YS, Altieri B, Berhane S, Cosentini D, Calabrese A, Haissaguerre M, Kastelan D, Fragoso MCBV, Bertherat J, Al Ghuzlan A, Haak H, Boudina M, Canu L, Loli P, Sherlock M, Kimpel O, Laganà M, Sitch AJ, Kroiss M, Arlt W, Terzolo M, Berruti A, Deeks JJ, Libé R, Fassnacht M, Ronchi. Adrenocortical carcinoma: an international, multicenter ENSAT study. CL Eur J Endocrinol. 2021;186(1):25–36.

Google Scholar 

Terzolo M, Fassnacht M, Perotti P, Libé R, Kastelan D, Lacroix A, Arlt W, Haak HR, Loli P, Decoudier B, Lasolle H, Quinkler M, Haissaguerre M, Chabre O, Caron P, Stigliano A, Giordano R, Zatelli MC, Bancos I, Fragoso MCBV, Canu L, Luconi M, Puglisi S, Basile V, Reimondo G, Kroiss M, Megerle F, Hahner S, Kimpel O, Dusek T, Nölting S, Bourdeau I, Chortis V, Ettaieb MH, Cosentini D, Grisanti S, Baudin E, Berchialla P, Bovis F, Sormani MP, Bruzzi P, Beuschlein F, Bertherat J, Berruti A. Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study. Lancet Diabetes Endocrinol. 2023;11(10):720–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berruti A, Terzolo M, Sperone P, Pia A, Della Casa S, Gross DJ, Carnaghi C, Casali P, Porpiglia F, Mantero F, Reimondo G, Angeli A, Dogliotti L. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer. 2005;12(3):657–66.

Article  CAS  PubMed  Google Scholar 

Advances in adrenocortical, Abate A, Cosentini D, Grisanti S, Rossini E, Laganà M, Tamburello M, Turla A, Sigala S, Berruti AE. Carcinoma pharmacotherapy: what is the current state of the art?Cremaschi V. Opin Pharmacother. 2022;23(12):1413–24.

Article  Google Scholar 

Laganà M, Grisanti S, Cosentini D, Ferrari VD, Lazzari B, Ambrosini R, Sardini C, Volta AD, Palumbo C, Poliani PL, Terzolo M, Sigala S, Tiberio GAM, Berruti A. Efficacy of the EDP-M scheme plus adjunctive surgery in the management of patients with advanced adrenocortical carcinoma: the Brescia experience. Cancers (Basel). 2020;12(4):941. https://doi.org/10.3390/cancers12040941. PMID: 32290298; PMCID: PMC7226395.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vesselle H, Salskov A, Turcotte E, Wiens L, Schmidt R, Jordan CD, Vallières E, Wood DE. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index. J Thorac Oncol. 2008;3(9):971–8. https://doi.org/10.1097/JTO.0b013e31818307a7

Bellini P, Albano D, Dondi F, Bertagna F, Giubbini R Different glucose metabolism behavior relating to histotypes in synchronous breast cancers evaluated by [18F]FDG PET-CT. Nucl Med Rev Cent East Eur. 2022;25(1):64–5. . https://doi.org/10.5603/NMR.a2022.0012.

Article  PubMed  Google Scholar 

Dondi F, Albano D, Bellini P, Cerudelli E, Treglia G, Bertagna F. Prognostic role of baseline 18F-FDG pet/CT in stage I and stage Ii non-small cell lung cancer. Clin Imaging. 2023;94:71–8. Epub 2022 Dec 2. PMID: 36495848.

Article  PubMed  Google Scholar 

Dondi F, Pasinetti N, Guerini A, Piazza C, Mattavelli D, Bossi P, Berruti A, Ravanelli M, Farina D, Albano D, Treglia G, Bertagna F. Prognostic role of baseline 18 F-FDG pet/CT in squamous cell carcinoma of the paranasal sinuses. Head Neck. 2022;44(11):2395–406. https://doi.org/10.1002/hed.27145. Epub 2022 Jul 12. PMID: 35818852.

Article  PubMed  Google Scholar 

Wrenn SM, Moore AL, Shah HJ, Barletta JA, Vaidya A, Kilbridge KL, Doherty GM, Jacene HA, Nehs MA. Higher SUVmax on FDG-PET is associated with shorter survival in adrenocortical carcinoma. Am J Surg. 2023;225(2):309–14. Epub 2022 Sep 8. PMID: 36137821.

Article  PubMed  Google Scholar 

Satoh K, Patel D, Dieckmann W, Nilubol N, Kebebew E. Whole body metabolic tumor volume and total lesion Glycolysis predict survival in patients with adrenocortical carcinoma. Ann Surg Oncol. 2015;22(Suppl 3):S714–20. https://doi.org/10.1245/s10434-015-4813-8. Epub 2015 Aug 18. PMID: 26282908.

Article  PubMed  Google Scholar 

Schlötelburg W, Hartrampf PE, Kosmala A, Fuss CT, Serfling SE, Buck AK, Schirbel A, Kircher S, Hahner S, Werner RA, Fassnacht M. Prognostic role of quantitative [18F]FDG PET/CT parameters in adrenocortical carcinoma. Endocrine. 2024;84(3):1172–81. https://doi.org/10.1007/s12020-024-03695-6. Epub 2024 Feb 21. PMID: 38381353; PMCID: PMC11208261.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tessonnier L, Ansquer C, Bournaud C, Sebag F, Mirallié E, Lifante JC, Palazzo FF, Morange I, Drui D, de la Foucardère C, Mancini J, Taïeb D (18)F-FDG uptake at initial staging of the adrenocortical cancers: a diagnostic tool but not of prognostic value. World J Surg. 2013;37(1):107–12. . https://doi.org/10.1007/s00268-012-1802-y.

Article  CAS  PubMed  Google Scholar 

Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, Stroobants S, Delbeke D, Donohoe KJ, Holbrook S, Graham MM, Testanera G, Hoekstra OS, Zijlstra J, Visser E, Hoekstra CJ, Pruim J, Willemsen A, Arends B, Kotzerke J, Bockisch A, Beyer T, Chiti A, Krause BJ. European association of nuclear medicine (EANM). FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54. https://doi.org/10.1007/s00259-014-2961-x.

Article  CAS  PubMed  Google Scholar 

Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la Fouchardière C, Schlumberger M, Mantero F, Weismann D, Beuschlein F, Gelderblom H, Wilmink H, Sender M, Edgerly M, Kenn W, Fojo T, Müller HH, Skogseid B, FIRM-ACT Study Group. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366(23):2189–97. https://doi.org/10.1056/NEJMoa1200966. Epub 2012 May 2. PMID: 22551107.

Article  CAS  PubMed  Google Scholar 

Deandreis D, Leboulleux S, Caramella C, Schlumberger M, Baudin E. FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma. Horm Cancer. 2011;2(6):354–62. https://doi.org/10.1007/s12672-011-0091-5. PMID: 22076881; PMCID: PMC10358045.

Article  PubMed  PubMed Central  Google Scholar 

Krishnaraju VS, Kumar R, Subramanian K, Mittal BR, Singh H, Chatterjee D, Walia R. Fluoro-2-deoxyglucose-positron emission tomography/computed tomography in the diagnosis and management of adrenocortical carcinoma: a 10-year experience from a tertiary care Institute. Indian J Nucl Med. 2022;37(3):227–35.

Article  PubMed  PubMed Central  Google Scholar 

Hahner S, Higuchi T, Serfling SE, Samnick S, Fuss CT, Heinze B, Buck AK, Schirbel A, Fassnacht M, Werner RA. Exploring theranostic avenues in adrenocortical carcinoma using chemokine receptor and Prostate-Specific membrane Antigen-Directed PET/CT. Clin Nucl Med. 2024;49(4):369–70. Epub 2024 Feb 9. PMID: 38350087.

Article  PubMed  Google Scholar 

Leboulleux S, Dromain C, Bonniaud G, Aupérin A, Caillou B, Lumbroso J, Sigal R, Baudin E, Schlumberger M. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab. 2006;91(3):920–5. https://doi.org/10.1210/jc.2005-1540. Epub 2005 Dec 20. PMID: 16368753.

Article  CAS  PubMed  Google Scholar 

Takeuchi S, Balachandran A, Habra MA, Phan AT, Bassett RL Jr, Macapinlac HA, Chuang HH Impact of ¹⁸F-FDG PET/CT on the management of adrenocortical carcinoma: analysis of 106 patients. Eur J Nucl Med Mol Imaging. 2014;41(11):2066–73. . https://doi.org/10.1007/s00259-014-2834-3.

Article  PubMed  Google Scholar 

Lodge MA. Repeatability of SUV in oncologic 18F-FDG PET. J Nucl Med. 2017;58(4):523–32. https://doi.org/10.2967/jnumed.116.186353. Epub 2017 Feb 23. PMID: 28232605; PMCID: PMC5373499.

Article  CAS  PubMed  PubMed Central  Google Scholar